• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The contribution  of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study
ConclusionsGenotype-guided selection of P2Y12 inhibitor made a very positive contribution on the prognosis in Chinese ACS/CCS patients undergoing PCI. Instead of intensifying antiplatelet strategies, conventional-dose clopidogrel could be recommended as P2Y12 inhibitor after weighing MACEs and bleeding events in CYP2C19 IM patients.
Source: European Journal of Clinical Pharmacology - July 14, 2023 Category: Drugs & Pharmacology Source Type: research

The effect of perioperative diuretic administration on acute kidney injury in patients with acute myocardial infarction after percutaneous coronary intervention: a real-world retrospective study
ConclusionWe found no significant association between perioperative diuretic administration and postoperative CI-AKI in patients with AMI who underwent PCI.
Source: European Journal of Clinical Pharmacology - July 1, 2023 Category: Drugs & Pharmacology Source Type: research

Effect of frailty on major bleeding in octogenarian patients undergoing percutaneous coronary intervention
CONCLUSIONS: Frailty is an independent predictor of major bleeding in patients undergoing PCI for acute coronary syndrome. Use of the P2Y12 inhibitor ticagrelor increases the risk of major bleeding in frail patients.PMID:37318490 | DOI:10.26355/eurrev_202306_32633
Source: European Review for Medical and Pharmacological Sciences - June 15, 2023 Category: Drugs & Pharmacology Authors: K Özbek A Balun Source Type: research

Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score-Matched Cohort Study
The objective of this study was to evaluate cardiovascular events based on ticagrelor, prasugrel, and clopidogrel use in a real-world patient setting. This retrospective cohort study used the IBM MarketScan database (January 1st, 2013, to December 31st, 2018) to create 3 propensity score-matched pairs: ticagrelor vs. clopidogrel (N=21,719), prasugrel vs. clopidogrel (N=11,513), and prasugrel vs. ticagrelor (N=11,065). The primary outcome was a composite of myocardial ischemia, unstable angina, stroke, and heart failure hospitalization. These groups were compared in a time-to-event analysis for the primary outcome at 30, 90...
Source: Clinical Pharmacology and Therapeutics - November 18, 2022 Category: Drugs & Pharmacology Authors: Arun Kumar Pamela L Lutsey Wendy L St Peter Jon C Schommer Jeremy R Van't Hof Abhijeet Rajpurohit Joel F Farley Source Type: research

Pages: 1  2  3  4  5  6  7  8  9